Skip to main content

Table 2 Multivariable regression models for objective assessment and TDM performance in the 12 weeks prior to therapy change (either dose change or discontinuation)

From: Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

  At least one objective assessmenta TDM performed
OR 95% CI p value OR 95% CI p value
Sex (female vs. male) 0.849 0.565–1.274 0.4283 1.480 0.929–2.361 0.0993
Race (white vs. nonwhite) 0.657 0.330–1.306 0.2305 1.152 0.540–2.456 0.7147
Age at therapy change (years) 1.004 0.989–1.019 0.6215 0.996 0.979–1.013 0.6164
Previous biologic use (yes vs. no) 1.027 0.639–1.652 0.9120 0.980 0.5840–1.642 0.9378
Disease duration at therapy change (years) 0.987 0.964–1.011 0.2896 0.997 0.969–1.025 0.8133
Site type (academic vs. community) 1.588 1.010–2.495 0.0452 1.114 0.662–1.875 0.6845
Private insurance at enrollment (yes vs. no) 1.044 0.602–1.811 0.8781 1.188 0.626–2.253 0.5979
Drug classb    0.0083    
 Adalimumab Ref Ref Ref Ref Ref
 Infliximab 0.569 0.360–0.900 0.0159 0.844 0.529–1.348 0.4779
 Other anti-TNF 1.460 0.576–3.705 0.4252    
 Ustekinumab 0.353 0.137–0.914 0.0320    
 Vedolizumab 1.359 0.683–2.702 0.3819    
Disease type (CD vs. UC) 1.181 0.734–1.901 0.4923 0.953 0.567–1.602 0.8566
Therapy change (discontinuation vs. dose change) 1.178 0.776–1.788 0.4417 1.011 0.634–1.613 0.9632
  1. aObjective assessment included fecal calprotectin, C-reactive protein, endoscopy, MRI, or CT scan
  2. bFor TDM model, drug class compared infliximab to adalimumab (reference) as these were the only two biologics included in the TDM assessment population